Legislation to encourage generic drug entry introduced in House and Senate

AHA News Now

Sen. Patrick Leahy (D-VT) and other members of the Senate and House Judiciary committees today introduced the Creating and Restoring Equal Access to Equivalent Samples Act, which targets anticompetitive behaviors used to block and delay entry of generic drugs. Among other provisions, the bipartisan... read more

Topic: Advocacy and Public Policy
Tag: drug prices

Hearings highlight how restrictive use programs can limit generic competition

AHA News Now

A subcommittee of the House Oversight and Government Reform Committee today held a hearing to examine how drug makers may misuse voluntary restricted distribution systems to delay or block generic competition. Janet Woodcock, M.D., director of the Food and Drug Administration’s Center for Drug Evaluation... read more

Topic: Advocacy and Public Policy
Tag: drug prices

HRSA further delays effective date of final rule on 340B drug ceiling prices

AHA News Now

The Health Resources and Services Administration today delayed to May 22 the effective date of its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers, and invited comments on whether a delay to Oct. 1 would be more appropriate. The rule was set to take effect March 21... read more

Topic: Advocacy and Public Policy
Tags: 340B, Drug Pricing Program, regulation, drug prices

AHA Stat blog: Congress should protect the 340B program

AHA News Now

“Congress should preserve the 340B Drug Pricing Program and protect patients and communities,” writes AHA Executive Vice President Tom Nickels in an AHA Stat blog post. He notes, “Every day, we see stories about the exorbitant costs of prescription drugs and the serious challenges they pose for... read more

Topic: Advocacy and Public Policy
Tags: 340B, Drug Pricing Program, drug prices

Reminder: AHA webinar March 16 on strategies to address rising medication costs

AHA News Now

The AHA will host a free webinar March 16 on strategies to address rising medication costs. The event will feature a case study by The Ohio State University Wexner Medical Center. For more information and to register, click here.

Topic: Advocacy and Public Policy
Tag: drug prices

MedPAC considers reforms to Part B drug payment policy

AHA News Now

The Medicare Payment Advisory Commission yesterday discussed a package of draft recommendations to reduce the rapid growth in Part B drug spending. The proposals would require all Part B drug manufacturers to submit Average Sales Price data; reduce Wholesale Acquisition Cost-based payment to WAC plus 3%;... read more

Topic: Advocacy and Public Policy
Tags: Meaningful Use, EHRs, Electronic Health Records, Medicare, drug prices

AHA webinar March 16 on strategies to address rising medication costs

AHA News Now

The AHA will host a free webinar March 16 on strategies to address rising medication costs. The event will feature a case study by The Ohio State University Wexner Medical Center. For more information and to register, click here.

Topic: Advocacy and Public Policy
Tag: drug prices

Express Scripts reports on 2016 drug spending by health plan clients

AHA News Now

Drug spending per member for public health insurance exchange plans sponsored by Express Scripts clients increased 14% in 2016, driven by increases in both unit costs and use, according to a new report by the pharmacy benefit management company. Drug spending per member for Medicaid, Medicare Part D, and... read more

Topic: Access and Coverage
Tag: drug prices

AHA brief examines how hospitals are holding the line on costs

AHA News Now

Hospitals and health systems have been leaders in controlling costs in the health care sector, with hospital price growth in 2015 at the slowest annual rate since 1998 and Medicare spending growth for hospital services at its lowest level in 17 years, according to a data brief on hospital care costs... read more

Topic: Advocacy and Public Policy
Tags: Electronic Health Records, Coverage, regulation, workforce, chronic conditions, drug prices

CMS: Part D drug rebates/price concessions raise beneficiary costs, subsidies

AHA News Now

Manufacturer rebates and other price concessions reported by Medicare Part D prescription drug plans after the point-of-sale grew about 22% annually between 2010 and 2015, contributing to higher beneficiary cost-sharing and Medicare subsidy payments, according to a report released last week by the Centers... read more

Topic: Advocacy and Public Policy
Tag: drug prices

Keyword Search

Date